TN2021000169A1 - Anti-alpha-synuclein antibodies - Google Patents
Anti-alpha-synuclein antibodiesInfo
- Publication number
- TN2021000169A1 TN2021000169A1 TNP/2021/000169A TN2021000169A TN2021000169A1 TN 2021000169 A1 TN2021000169 A1 TN 2021000169A1 TN 2021000169 A TN2021000169 A TN 2021000169A TN 2021000169 A1 TN2021000169 A1 TN 2021000169A1
- Authority
- TN
- Tunisia
- Prior art keywords
- alpha
- alpha synuclein
- antibodies
- synuclein antibodies
- fibrils
- Prior art date
Links
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 4
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 4
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1720975.0A GB201720975D0 (en) | 2017-12-15 | 2017-12-15 | Anti-alpha synuclein antibodies |
PCT/EP2018/084697 WO2019115674A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2021000169A1 true TN2021000169A1 (en) | 2023-04-04 |
Family
ID=61009086
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP/2021/000169A TN2021000169A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
TNP/2020/000069A TN2020000069A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP/2020/000069A TN2020000069A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
Country Status (25)
Country | Link |
---|---|
US (2) | US11261242B2 (en) |
EP (1) | EP3724224A1 (en) |
JP (2) | JP7292279B2 (en) |
KR (1) | KR20200099160A (en) |
CN (1) | CN111479826A (en) |
AR (1) | AR115192A1 (en) |
AU (1) | AU2018382530A1 (en) |
BR (1) | BR112020010504A2 (en) |
CA (1) | CA3083199A1 (en) |
CL (1) | CL2020001605A1 (en) |
EA (1) | EA202091478A1 (en) |
EC (1) | ECSP20039623A (en) |
GB (1) | GB201720975D0 (en) |
IL (1) | IL275187A (en) |
MA (1) | MA51135A (en) |
MX (1) | MX2020005691A (en) |
PE (1) | PE20201061A1 (en) |
PH (1) | PH12020551007A1 (en) |
SG (1) | SG11202004502SA (en) |
TN (2) | TN2021000169A1 (en) |
TW (2) | TWI801469B (en) |
UA (1) | UA126295C2 (en) |
UY (1) | UY38010A (en) |
WO (1) | WO2019115674A1 (en) |
ZA (2) | ZA202003542B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018151821A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
EP3867270A1 (en) * | 2018-10-19 | 2021-08-25 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
WO2021055881A1 (en) * | 2019-09-20 | 2021-03-25 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
WO2021113464A1 (en) * | 2019-12-04 | 2021-06-10 | Friedman Simon | Protein blocking assembly and methods of making and using |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
JP4055579B2 (en) | 2000-12-13 | 2008-03-05 | 大正製薬株式会社 | New antibody |
US7479482B2 (en) | 2001-11-21 | 2009-01-20 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
HUE034320T2 (en) | 2003-05-19 | 2018-02-28 | Prothena Biosciences Ltd | Truncated fragments of alpha-synuclein in lewy body disease |
US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
EA013752B1 (en) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
PL3067066T3 (en) * | 2007-02-23 | 2019-09-30 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
PL2118300T3 (en) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2009133521A2 (en) | 2008-04-29 | 2009-11-05 | Bioartic Neuroscience Ab | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
EP2949666B1 (en) | 2008-12-19 | 2018-12-19 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
JP5894939B2 (en) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | Protofibril binding antibodies and their use in methods of treatment and diagnosis of Parkinson's disease, Lewy body dementia and other alpha-synucleinopathies |
EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
WO2012061786A1 (en) | 2010-11-05 | 2012-05-10 | Brandeis University | Ice cleaved alpha-synuclein a biomarker |
DE102011008153B4 (en) | 2011-01-08 | 2018-08-09 | Aj Roboscreen Gmbh | Process for the preparation of a monoclonal antibody against oligomeric alpha-synuclein |
AU2012272790B2 (en) | 2011-06-23 | 2016-10-06 | Biogen International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
EP3378535B1 (en) | 2011-10-28 | 2023-01-04 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
CA2863953A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
DK2857419T3 (en) | 2012-05-30 | 2021-03-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule for the elimination of aggregated antigens |
UA118441C2 (en) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
JP2017501848A (en) | 2013-11-19 | 2017-01-19 | プロセナ バイオサイエンシーズ リミテッド | Monitoring immunotherapy of Lewy body disease from constipation symptoms |
KR102358311B1 (en) * | 2013-11-21 | 2022-02-08 | 에프. 호프만-라 로슈 아게 | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
US10155030B2 (en) | 2014-05-23 | 2018-12-18 | University Of South Florida | Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
CN107208125A (en) | 2014-09-11 | 2017-09-26 | 德克萨斯大学系统董事会 | The detection of misfolded proteins matter |
WO2016040903A1 (en) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded amyloid beta protein |
WO2016040905A1 (en) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded alpha synuclein protein |
CN107074938A (en) | 2014-10-16 | 2017-08-18 | 豪夫迈·罗氏有限公司 | Anti alpha synapse nucleoprotein antibody and application method |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
US10852309B2 (en) | 2015-08-25 | 2020-12-01 | Prothena Biosciences Limited | Methods for detecting phosphorylated alpha-synuclein |
EP3380622A4 (en) | 2015-11-23 | 2019-08-07 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
WO2017176835A2 (en) | 2016-04-06 | 2017-10-12 | Imago Pharmaceuticals, Inc. | Therapeutic antibodies for treatment of neurodegeneration |
AU2017272804B2 (en) | 2016-06-02 | 2023-11-23 | Medimmune Limited | Antibodies to alpha-synuclein and uses thereof |
GB201611840D0 (en) | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
US20190194324A1 (en) | 2016-08-23 | 2019-06-27 | The Johns Hopkins University | THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTOR |
WO2018091444A1 (en) | 2016-11-15 | 2018-05-24 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
US20180134775A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (7A11) |
US20180134776A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (4H6) |
US20180134777A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (11D12) |
AU2017376670A1 (en) | 2016-12-12 | 2019-07-18 | The Michael J. Fox Foundation For Parkinson's Research | Antibodies to human alpha-synuclein |
US11325968B2 (en) | 2016-12-16 | 2022-05-10 | H. Lundbeck A/S | Alpha-synuclein antibodies |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
EP3567054A4 (en) | 2017-01-06 | 2021-03-10 | ABL Bio Inc. | Anti-alpha-syn antibody and use thereof |
WO2018128722A1 (en) | 2017-01-09 | 2018-07-12 | California Institute Of Technology | Use of gut microbiota in the diagnosis and therapeutics of parkinson's disease |
WO2018151821A1 (en) * | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
JOP20190227A1 (en) | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | Compositions and methods for treating synucleinopathies |
MX2019013589A (en) | 2017-05-16 | 2020-07-20 | Claudio Soto Jara | Detection of misfolded tau protein. |
WO2018237338A1 (en) | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
-
2017
- 2017-12-15 GB GBGB1720975.0A patent/GB201720975D0/en not_active Ceased
-
2018
- 2018-12-13 PE PE2020000707A patent/PE20201061A1/en unknown
- 2018-12-13 EA EA202091478A patent/EA202091478A1/en unknown
- 2018-12-13 SG SG11202004502SA patent/SG11202004502SA/en unknown
- 2018-12-13 BR BR112020010504-0A patent/BR112020010504A2/en unknown
- 2018-12-13 KR KR1020207019487A patent/KR20200099160A/en unknown
- 2018-12-13 EP EP18829767.5A patent/EP3724224A1/en active Pending
- 2018-12-13 WO PCT/EP2018/084697 patent/WO2019115674A1/en active Application Filing
- 2018-12-13 TN TNP/2021/000169A patent/TN2021000169A1/en unknown
- 2018-12-13 AU AU2018382530A patent/AU2018382530A1/en active Pending
- 2018-12-13 TN TNP/2020/000069A patent/TN2020000069A1/en unknown
- 2018-12-13 US US16/771,993 patent/US11261242B2/en active Active
- 2018-12-13 CA CA3083199A patent/CA3083199A1/en active Pending
- 2018-12-13 MX MX2020005691A patent/MX2020005691A/en unknown
- 2018-12-13 CN CN201880080854.1A patent/CN111479826A/en active Pending
- 2018-12-13 MA MA051135A patent/MA51135A/en unknown
- 2018-12-13 UA UAA202002941A patent/UA126295C2/en unknown
- 2018-12-13 JP JP2020532596A patent/JP7292279B2/en active Active
- 2018-12-14 TW TW107145283A patent/TWI801469B/en active
- 2018-12-14 UY UY0001038010A patent/UY38010A/en not_active Application Discontinuation
- 2018-12-14 TW TW112114559A patent/TW202332692A/en unknown
- 2018-12-14 AR ARP180103657A patent/AR115192A1/en unknown
-
2020
- 2020-06-07 IL IL275187A patent/IL275187A/en unknown
- 2020-06-12 ZA ZA2020/03542A patent/ZA202003542B/en unknown
- 2020-06-14 PH PH12020551007A patent/PH12020551007A1/en unknown
- 2020-06-15 CL CL2020001605A patent/CL2020001605A1/en unknown
- 2020-07-14 EC ECSENADI202039623A patent/ECSP20039623A/en unknown
-
2021
- 2021-05-21 ZA ZA2021/03456A patent/ZA202103456B/en unknown
-
2022
- 2022-01-26 US US17/585,174 patent/US20220220192A1/en active Pending
-
2023
- 2023-06-05 JP JP2023092397A patent/JP2023127585A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551006A1 (en) | Anti-alpha synuclein antibodies | |
PH12020551007A1 (en) | Anti-alpha-synuclein antibodies | |
PH12019502793A1 (en) | Aadc polynucleotides for the treatment of parkinson`s disease | |
MX2019012233A (en) | Anti-sirp alpha antibodies. | |
MD4733B1 (en) | Anti-TIGIT antibodies | |
MX2017005834A (en) | Aadc polynucleotides for the treatment of parkinson's disease. | |
MX2020001513A (en) | Clec9a binding agents and use thereof. | |
NZ739499A (en) | Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof | |
MX2019009117A (en) | Antibodies to alpha-synuclein and uses thereof. | |
PH12017500032A1 (en) | Improved a� protofibril binding antibodies | |
UA117096C2 (en) | Polypeptides binding to human complement c5 | |
MX2015015249A (en) | Therapeutic peptides. | |
WO2011112867A8 (en) | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | |
MX2022002635A (en) | Angiopoietin-like 4 antibodies and methods of use. | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
MX2018014129A (en) | Pharmaceutical composition comprising eteplirsen. | |
MX2020000636A (en) | Synthetic proteins and therapeutic uses thereof. | |
MX2016008968A (en) | Organic compounds. | |
IL260009B (en) | Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease | |
WO2019004970A3 (en) | Heterobivalent ligands suitable for use in the treatment of parkinson's disease |